Gene Therapy FAQ

None of these therapies would exist without regulatory frameworks specifically designed to incentivize rare disease drug development. In the United States, the Orphan Drug Act of 1983 was a landmark piece of legislation that transformed the landscape. Before the Act, fewer than 40 drugs had been approved for rare diseases. The Act offered pharmaceutical companies a package of incentives: seven years of market exclusivity, tax credits for clinical research costs, waived FDA application fees, and access to grants for clinical research.

The defining characteristic of a rare disease is its low prevalence. But beyond the numbers, rare diseases share several features that make them uniquely challenging. The majority — roughly 80%, according to the National Institutes of Health — have a genetic origin. Many are monogenic, meaning they are caused by mutations in a single gene. Conditions like spinal muscular atrophy (SMA), sickle cell disease, hemophilia B, Duchenne muscular dystrophy, and Leber congenital amaurosis all trace their devastation to errors in one gene.

Gene therapies are expensive due to three compounding factors: manufacturing complexity (each patient's therapy is produced individually with no economies of scale), small patient populations (R&D costs of $1-3 billion must be recovered across hundreds of patients per year), and the one-time curative model that attempts to capture a lifetime of therapeutic value in a single upfront payment. The cost of viral vectors alone — such as lentiviral or AAV vectors — runs into the hundreds of thousands of dollars per batch.

Imagine being told, as a toddler's parent, that your child will need a blood transfusion every two to four weeks for the rest of their life. That without these transfusions, the severe anemia caused by their genetic condition will lead to growth failure, bone deformities, organ damage, and early death. That even with transfusions, iron will slowly accumulate in the heart, liver, and endocrine organs, requiring daily chelation therapy and constant monitoring — a second treatment burden layered on top of the first.

The Cystic Fibrosis Foundation, which has a storied history of de-risking drug development in CF (its $75 million investment in Vertex Pharmaceuticals helped fund the development of the modulator drugs), signaled its confidence in prime editing with a landmark investment. In 2023, the Foundation committed $39 million to Prime Medicine, the company co-founded by David Liu to develop prime editing therapeutics, specifically to advance a prime editing therapy for cystic fibrosis through preclinical development.

Accelerated approval depends on surrogate endpoints being "reasonably likely to predict clinical benefit." For some gene therapies, the surrogate-to-outcome link is strong: if you restore Factor VIII activity to near-normal levels in a hemophilia A patient, reduced bleeding is virtually certain. For others, the link is weaker. Does a 30% increase in enzyme activity in a lysosomal storage disorder translate to meaningful clinical improvement? Possibly, but the correlation is not always linear or predictable.

The approval of Trikafta (elexacaftor/tezacaftor/ivacaftor) by the FDA in October 2019 was, by any measure, one of the most important advances in the history of cystic fibrosis treatment. This triple-combination CFTR modulator therapy works by partially correcting the underlying protein defect: elexacaftor and tezacaftor act as "correctors" that help the F508del-CFTR protein fold properly and reach the cell surface, while ivacaftor is a "potentiator" that holds the channel open once it arrives.

Papzimeos represents a different category of cell therapy. Rather than modifying a gene, it uses an ex vivo expansion technology to enhance umbilical cord blood stem cells for transplantation. Cord blood transplant has long been limited by the small number of stem cells available in a single cord blood unit. Papzimeos uses a nicotinamide-based expansion process to increase the number of stem cells, enabling faster engraftment and reducing the period of severe immune deficiency after transplant.

For patients who have received these therapies, the impact goes beyond clinical metrics. Victoria Gray, one of the first patients treated with Casgevy in a clinical trial, described the transformation as getting her life back. After years of hospitalizations, pain crises, and dependence on opioids, she has been crisis-free since her treatment in 2019. Stories like hers are powerful — but they also highlight the gap between the promise of gene therapy and its current reach.

Gene therapy has entered a new era. Since Casgevy became the first CRISPR-based treatment to win FDA approval in December 2023, the pipeline of gene and cell therapies approaching the clinic has exploded. As of early 2026, over 3,000 gene therapy clinical trials are active or recruiting worldwide, targeting everything from sickle cell disease to hereditary blindness to solid tumors. The science is moving fast. The question is whether the regulatory machinery can keep pace.

Gene therapies are regulated by the FDA's Center for Biologics Evaluation and Research (CBER), specifically the Office of Tissues and Advanced Therapies (OTAT). This is a different division from the one that handles conventional drugs (CDER), and the distinction matters. Biologics — including gene therapies, cell therapies, and vaccines — follow the Biologics License Application (BLA) pathway rather than the New Drug Application (NDA) pathway used for small-molecule drugs.

Spinal muscular atrophy (SMA) is a devastating genetic disorder that attacks the nerve cells responsible for voluntary muscle movement. It is caused by mutations in the SMN1 gene on chromosome 5, which provides instructions for making the survival motor neuron (SMN) protein. Without sufficient levels of this protein, motor neurons in the spinal cord degenerate and die, leading to progressive muscle weakness that can affect breathing, swallowing, and movement.

In July 2024, a paper published in Nature Biomedical Engineering by researchers at the Broad Institute of MIT and Harvard and the University of Iowa sent a ripple of excitement through the CF community. The team, led by David Liu and Paul McCray, demonstrated that prime editing could correct the F508del mutation in human airway epithelial cells with an efficiency of up to 58% — a level that far exceeds what is thought to be necessary for therapeutic benefit.

More than 2,100 mutations in the CFTR gene have been identified, but one dominates the landscape. The F508del mutation — a deletion of three nucleotides that removes a single phenylalanine amino acid at position 508 of the CFTR protein — is present in approximately 85% of CF patients worldwide. About 45% of patients carry two copies of F508del (homozygous), and another 40% carry F508del on one chromosome alongside a different CFTR mutation on the other.

Medicare covers all FDA-approved CAR-T therapies. Under the current Medicare payment system, hospitals receive a lump-sum payment through the New Technology Add-on Payment (NTAP) mechanism, which in recent years has covered a substantial portion -- but not always all -- of the drug acquisition cost. Hospitals that administer CAR-T to Medicare patients may absorb a financial loss on some cases, which has led to access concerns at community hospitals.

Sickle cell disease (SCD) is one of the most common inherited blood disorders in the world, affecting an estimated 20 million people globally, with the highest prevalence in sub-Saharan Africa, India, and communities of African descent in the Americas. The disease is caused by a single point mutation in the HBB gene, which encodes the beta-globin subunit of hemoglobin — the protein in red blood cells that carries oxygen throughout the body.

The most fundamental criticism is that the plausible mechanism pathway lowers the evidentiary standard for one of the most consequential categories of medical intervention. Gene therapies that edit the genome make permanent changes to a patient's DNA. Unlike a drug that can be discontinued if it causes problems, a gene edit cannot be taken back. The permanence of the intervention argues for more evidence before approval, not less.

The word "success" in oncology requires careful definition. Clinicians typically measure outcomes in terms of overall response rate (ORR), complete remission rate (CR), duration of response, progression-free survival (PFS), and overall survival (OS). For patients, the most meaningful number is often the complete remission rate -- the percentage of patients whose cancer becomes undetectable -- and how long that remission lasts.

Kymriah holds the distinction of being the first gene therapy of any kind approved by the FDA. On August 30, 2017, the agency cleared it for the treatment of pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. This was a population with few remaining options and dismal prognosis -- many of these patients had a life expectancy measured in months.

Beta-thalassemia is an inherited blood disorder caused by mutations in the HBB gene, which provides the instructions for making beta-globin — one of the two protein subunits that form adult hemoglobin (HbA). Hemoglobin is the molecule inside red blood cells that carries oxygen from the lungs to every tissue in the body. Each hemoglobin molecule consists of four subunits: two alpha-globin chains and two beta-globin chains.

Gene editing tools like CRISPR-Cas9 are extraordinarily precise, but precision means nothing if the molecular machinery cannot reach the right cells inside the body. The gene editing components -- a Cas9 protein or its mRNA, plus a guide RNA -- must cross the cell membrane, escape degradation, and reach the nucleus to do their work. Naked RNA injected into the bloodstream would be destroyed by nucleases within minutes.

CAR-T cell therapy represents one of the most significant advances in cancer treatment in the past two decades. By genetically reprogramming a patient's own immune cells to hunt and destroy cancer, it has produced durable remissions in patients who had exhausted every other option. But alongside the remarkable clinical outcomes comes a stark reality: CAR-T is among the most expensive medical treatments ever developed.

Cystic fibrosis is one of the most common life-shortening genetic diseases in the world. Approximately 70,000 people live with it globally, with the highest prevalence among people of Northern European descent, where roughly 1 in 25 individuals carries a single copy of a disease-causing mutation. When two carriers have a child, there is a 1 in 4 chance that child will inherit two faulty copies and develop the disease.

Writing about gene therapy for DMD requires holding two truths at once. The first is that this is real, meaningful progress. A decade ago, there was no gene therapy for DMD at any stage. Today, there is an approved treatment, multiple candidates in the pipeline, and a CRISPR approach that could fundamentally change the disease. Families living with DMD today have more reason for hope than at any point in history.

Hemophilia is a group of inherited bleeding disorders caused by deficiencies in specific clotting factors — proteins that work together in a cascade to form blood clots and stop bleeding. Without adequate levels of these proteins, even minor injuries can lead to prolonged bleeding. Spontaneous bleeding into joints, muscles, and internal organs is common in severe cases and can be debilitating or life-threatening.

Shortly after its sickle cell approval, Casgevy also received FDA approval for transfusion-dependent beta-thalassemia (TDT), another hemoglobin disorder. In TDT, patients require regular blood transfusions, sometimes every two to four weeks, to survive. The same BCL11A editing strategy works for both conditions because reactivating fetal hemoglobin addresses the underlying hemoglobin deficiency in TDT as well.

Beta-thalassemia is not a rare disease by global standards. It is estimated that approximately 60,000 to 70,000 children are born with severe forms of the disease each year worldwide. The carrier frequency is strikingly high in a broad geographic band stretching from the Mediterranean basin through the Middle East, the Indian subcontinent, and into Southeast Asia — a region often called the "thalassemia belt."

Consider a rare liver enzyme deficiency -- say, a condition caused by a loss-of-function mutation in a gene encoding a critical metabolic enzyme. The disease affects approximately 30 known patients in the United States. Without the functional enzyme, toxic metabolites accumulate, causing progressive liver damage, neurological deterioration, and typically death in the first decade of life. No treatment exists.

All six currently approved CAR-T therapies are autologous -- they are made from the patient's own cells. This personalized approach has significant advantages (lower risk of graft-versus-host disease, no need for donor matching) but also major drawbacks: high manufacturing cost, long turnaround times, and the risk that a patient's cells may be too damaged by prior treatments to produce an effective product.

The success of gene therapies for blood disorders (Casgevy, Lyfgenia for sickle cell disease), eye diseases (Luxturna for inherited retinal dystrophy), and liver conditions (Hemgenix for hemophilia B) has demonstrated that gene therapy can work brilliantly — when you can get the therapeutic payload to the right cells efficiently. The lung presents unique challenges that have stymied progress for decades.

For decades, hemophilia has been one of the most talked-about targets for gene therapy. The logic is straightforward: hemophilia is caused by a single missing protein. Deliver a working gene that produces that protein, and the disease should be corrected. In theory, a one-time infusion could replace a lifetime of intravenous clotting factor injections that cost hundreds of thousands of dollars per year.

The current generation of SCD gene therapies is remarkable but imperfect. The need for myeloablative conditioning, the high cost, and the logistical complexity of ex vivo cell manufacturing all limit scalability. The next frontier is in vivo gene therapy — delivering the editing machinery directly to stem cells inside the body, eliminating the need for cell extraction, conditioning, and reinfusion.

Duchenne muscular dystrophy (DMD) is a severe genetic disorder that causes progressive muscle degeneration and weakness. It is one of the most common fatal genetic diseases diagnosed in childhood, affecting approximately 1 in 3,500 to 5,000 male births worldwide. That translates to roughly 10,000 to 15,000 boys and young men living with DMD in the United States, and an estimated 300,000 worldwide.

One of the most important lessons from Zolgensma's clinical program is that timing matters enormously. Motor neurons, once lost, cannot be replaced. Gene therapy can preserve existing motor neurons by providing them with the SMN protein they need to survive, but it cannot resurrect neurons that have already degenerated. The implication is straightforward: earlier treatment yields better outcomes.

For patients with transfusion-dependent beta-thalassemia, the standard of care is regular red blood cell transfusions, typically every two to four weeks, to maintain hemoglobin levels above 9-10 g/dL. This regimen suppresses the body's own ineffective erythropoiesis, prevents bone marrow expansion, supports normal growth in children, and prevents the complications of chronic severe anemia.

Once the FDA accepts a BLA or NDA for review, the clock starts ticking. The agency assigns a Prescription Drug User Fee Act (PDUFA) date — the target date by which the FDA aims to complete its review. Standard reviews have a PDUFA date 10 months after submission. Priority reviews, granted for therapies that offer significant improvements over existing treatments, have a 6-month timeline.

While Casgevy and Zynteglo represent the first generation of approved gene therapies for TDT, the next wave is already in clinical testing. EDIT-301, developed by Editas Medicine, uses a different gene editing platform — Cas12a (formerly called Cpf1) — to target the same biological pathway as Casgevy: reactivation of fetal hemoglobin through disruption of the BCL11A erythroid enhancer.

One of the most powerful features of AAV is that it comes in many natural variants, called serotypes. Each serotype has a slightly different capsid structure, which means each one binds to different receptors on cell surfaces and enters different tissues with different efficiencies. This property is called tissue tropism — the natural preference of a virus for certain cell types.

Casgevy carries a list price of approximately $2.2 million per treatment — making it one of the most expensive therapies ever approved. For pediatric expansion, the cost equation becomes even more significant because more patients become eligible and the lifetime value of the treatment (measured in quality-adjusted life years gained) is theoretically greater in younger patients.

Traditional drug development follows a pattern: identify a disease mechanism, design a molecule that modulates that mechanism, test it in large clinical trials, and bring it to market. This approach works well for common diseases with large patient populations. For rare diseases, it often fails — not because the science is impossible, but because the economics do not add up.

Zynteglo (betibeglogene autotemcel, or beti-cel) was developed by bluebird bio and approved by the FDA in August 2022 for transfusion-dependent beta-thalassemia. It takes a fundamentally different approach from Casgevy: rather than editing an existing gene to reactivate fetal hemoglobin, Zynteglo adds a functional copy of a modified beta-globin gene to the patient's cells.

AAV stands for adeno-associated virus. It is one of the smallest known viruses, measuring only about 25 nanometers in diameter — roughly 4,000 times smaller than the width of a human hair. It was first discovered in 1965 as a contaminant in preparations of adenovirus (the virus behind many common colds), which is how it got its name: it was "associated" with adenoviruses.

In December 2023, the FDA approved two gene therapies for sickle cell disease within weeks of each other: Casgevy (exagamglocel autotemcel) from Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia (lovotibeglogene autotemcel) from bluebird bio. Both are one-time treatments designed to provide a functional cure, but they take fundamentally different approaches.

On February 12, 2026, the FDA published draft guidance titled "Individualized and Ultra-Rare Gene Therapies: A Risk-Based Framework for Regulatory Flexibility." This document introduced what the gene therapy community has quickly dubbed the "plausible mechanism" pathway — the most significant regulatory innovation for genetic medicine since the 21st Century Cures Act.

The most sobering aspect of these breakthroughs is accessibility. Casgevy's list price of approximately $2.2 million and Lyfgenia's price of approximately $3.1 million place them among the most expensive treatments ever approved. The total cost of treatment — including hospitalization, conditioning, monitoring, and supportive care — can exceed $4 million per patient.

The pivotal clinical trial data that supported FDA approval were striking. In the trial, 29 out of 31 evaluable patients (93.5%) were free from vaso-occlusive crises for at least 12 consecutive months following treatment. For patients who had previously experienced an average of several crises per year, this represented a dramatic transformation in quality of life.

Casgevy made history in December 2023 when the FDA approved it as the first CRISPR-Cas9 gene editing therapy ever authorized for clinical use. The approval covered two conditions: sickle cell disease (SCD) in patients aged 12 and older who experience recurrent vaso-occlusive crises (VOCs), and transfusion-dependent beta-thalassemia (TDT) in patients 12 and older.

Before discussing gene therapy strategies, it is important to understand that Parkinson's disease is not one disease. The majority of cases — roughly 85 to 90 percent — are idiopathic (sporadic), meaning no single genetic cause has been identified. These cases likely result from a complex interplay of genetic susceptibility, environmental exposures, and aging.

Casgevy (exagamglogene autotemcel, or exa-cel) was developed by Vertex Pharmaceuticals and CRISPR Therapeutics and became the first CRISPR-based gene therapy approved by any regulatory authority when the UK's MHRA approved it in November 2023 for both sickle cell disease and transfusion-dependent beta-thalassemia. FDA approval for TDT followed in January 2024.

Both therapies require myeloablative conditioning with busulfan, which carries significant risks including prolonged cytopenias, infection, veno-occlusive disease, and infertility. This conditioning step is currently the single greatest barrier to broader adoption of either therapy, and it is the focus of intense research efforts to find safer alternatives.

In November 2023, the UK's MHRA became the first regulatory body to approve Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The FDA followed in December 2023, and the EMA granted approval in early 2024. This marked the first time a CRISPR-based therapy was approved for clinical use anywhere in the world.

The gold standard of medical evidence is the randomized controlled trial (RCT): enroll a large group of patients, give half the real treatment and half a placebo, and measure the difference. This design has served medicine well for mass-market drugs. It requires, however, two things that rare diseases cannot provide: large numbers of patients and time.

The mainstay of Parkinson's treatment for over fifty years has been levodopa (L-DOPA), a precursor to dopamine. Dopamine itself cannot cross the blood-brain barrier, but levodopa can. Once inside the brain, levodopa is converted to dopamine by the enzyme aromatic L-amino acid decarboxylase (AADC), replenishing the depleted supply in the striatum.

bluebird bio is not the only gene therapy company to retreat from Europe. In 2024, BioMarin withdrew Roctavian, its gene therapy for hemophilia A, from the European market. Roctavian had received conditional approval from the European Medicines Agency (EMA) in August 2022, making it the first gene therapy approved for hemophilia A in any market.

The organizational home for gene therapy regulation — CBER — has undergone significant leadership changes that shape how these policies are implemented. Peter Marks, who served as Director of CBER from 2016 until his departure in March 2025, was widely regarded as one of the most consequential figures in the history of gene therapy regulation.

Casgevy carries a list price of approximately $2.2 million for a one-time treatment. Vertex Pharmaceuticals has argued that this price reflects the curative potential of the therapy and compares favorably to the lifetime cost of managing sickle cell disease, which has been estimated at $1.6 million to $6 million per patient over a lifetime.

On February 12, 2026, the FDA published a draft guidance document titled "Individualized and Ultra-Rare Gene Therapies: A Risk-Based Framework for Regulatory Flexibility." The document was issued by the Center for Biologics Evaluation and Research (CBER), the FDA division responsible for gene therapies, cell therapies, and other biologics.

Zynteglo, approved in August 2022, treats transfusion-dependent beta-thalassemia, a severe blood disorder in which patients require regular red blood cell transfusions every two to five weeks to survive. The therapy uses a lentiviral vector to insert a modified beta-globin gene (beta-A-T87Q) into the patient's own hematopoietic stem cells.

In April 2024, the FDA approved Pfizer's Beqvez (fidanacogene elaparvovec) for hemophilia B in adults. Like Hemgenix, Beqvez uses an AAV vector (an AAV variant called AAVrh74var in some descriptions, though Pfizer's vector is proprietary) carrying a FIX-Padua transgene to deliver a functional copy of the Factor IX gene to the liver.

Here is every major FDA-approved gene therapy in the United States as of March 2026, listed by price. These are manufacturer list prices (also called wholesale acquisition costs). The actual amount paid by insurers or hospitals is often negotiated lower, but list prices are the starting point for every financial conversation.

Lyfgenia takes a different approach. Instead of editing an existing gene, it uses a lentiviral vector to add a functional copy of a modified beta-globin gene (called beta-A-T87Q-globin) to the patient's stem cells. This engineered hemoglobin is designed to resist polymerization, functioning as an anti-sickling hemoglobin.

Casgevy is the world's first approved CRISPR-Cas9 therapy. Rather than trying to fix the sickle mutation directly, Casgevy uses an elegant workaround: it reactivates fetal hemoglobin (HbF), a form of hemoglobin that is naturally produced during fetal development and the first few months of life before being switched off.

Every gene therapy strategy for the brain confronts the same fundamental obstacle: the blood-brain barrier (BBB). This tightly sealed network of endothelial cells, astrocytes, and pericytes protects the brain from circulating pathogens and toxins — but it also blocks the entry of therapeutic vectors, including AAV.

The modern era of gene therapy in the United States began on August 30, 2017, when the FDA approved Kymriah, a CAR-T cell therapy for pediatric acute lymphoblastic leukemia. Within months, Yescarta followed for adult lymphoma, and Luxturna broke new ground as the first in vivo gene therapy for an inherited disease.

The Pfizer-BioNTech and Moderna COVID-19 vaccines brought LNP technology into the global spotlight. Both vaccines use LNPs to deliver mRNA encoding the SARS-CoV-2 spike protein. Billions of doses have been administered worldwide, providing an unprecedented safety and efficacy dataset for the LNP delivery platform.

Zolgensma (onasemnogene abeparvovec-xioi) takes a fundamentally different approach to treating SMA. Rather than modifying splicing of the backup SMN2 gene, it delivers a brand-new, fully functional copy of the SMN1 gene directly into the patient's cells. It is, in the most literal sense, gene replacement therapy.

Even among rare diseases, some conditions are so uncommon that they affect only a single patient — or are caused by unique, private mutations that require a bespoke therapeutic approach. This has given rise to the concept of "N-of-1" gene therapies: treatments designed and manufactured for a single individual.

The cystic fibrosis community was, in fact, among the first to pursue gene therapy. The cloning of the CFTR gene in 1989 by Lap-Chee Tsui, Francis Collins, and John Riordan was a landmark in human genetics, and within four years, clinical trials were underway to deliver a working copy of the gene to the lungs.

One of the key limitations of intravenous Zolgensma is that it is approved only for children under 2 years of age. The dose required for IV delivery scales with body weight, and treating older, heavier patients with the IV formulation would require impractically large doses with unacceptable toxicity risks.

As of early 2026, six CAR-T cell therapies have received FDA approval. Each targets a different set of cancers and carries a different list price for the drug itself. These prices do not include hospitalization, supportive care, or other associated costs -- those are discussed in a later section.

Getting FDA approval is not the end of the story. Phase 4 trials, also called post-marketing surveillance, begin after a therapy reaches the market. These studies monitor the therapy's safety and effectiveness in a much broader and more diverse patient population than clinical trials can capture.

Luxturna, approved in December 2017, was the first gene therapy for an inherited disease approved in the United States. It treats inherited retinal dystrophy caused by biallelic mutations in the RPE65 gene, a rare condition that causes progressive vision loss and can lead to complete blindness.

Elevidys (delandistrogene moxeparvovec), developed by Sarepta Therapeutics, is a one-time intravenous gene therapy that delivers a micro-dystrophin transgene using an AAV vector (specifically, AAVrh74 — a rhesus macaque-derived serotype with strong tropism for skeletal and cardiac muscle).

Three hundred million people. That is roughly the population of the United States, or more than the combined populations of Germany, France, Italy, and Spain. And yet, when it comes to medical research, drug development, and public awareness, these 300 million people are often invisible.

The pivotal clinical evidence for Zolgensma came from the phase I START trial, conducted at Nationwide Children's Hospital in Columbus, Ohio, and led by Dr. Jerry Mendell. The trial enrolled 15 infants with Type I SMA, all younger than 6 months at dosing and carrying two copies of SMN2.

As of early 2026, a growing number of gene therapies have received regulatory approval for rare diseases. Each one represents years of research, clinical trials, and advocacy — and for the patients and families affected, each one represents the difference between hope and hopelessness.

For decades, SMA management was purely supportive. Families facing a Type I diagnosis were told there was nothing that could change the trajectory of the disease. Physical therapy, respiratory support, nutritional management, and eventually palliative care were the standard of care.

The traditional insurance model — patient gets treated, insurer gets a bill, insurer pays — was designed for a world where the most expensive single treatment might cost $100,000. Gene therapies have broken that model. The healthcare system is improvising solutions in real time.

After a successful Phase 3 trial, the company submits a New Drug Application (NDA) for traditional drugs or a Biologics License Application (BLA) for biological products, including gene therapies. This is the formal request for the FDA to approve the therapy for commercial sale.

Imagine being told your child has a disease so rare that no pharmaceutical company has ever studied it. No clinical trial exists. No drug is approved. No treatment is even under development. The only medical advice available is palliative: manage symptoms, prepare for decline.

One of the most distinctive features of gene therapy regulation — regardless of which approval pathway is used — is the FDA's recommendation for 15 years of post-treatment monitoring for all patients who receive gene therapies involving genome integration or genome editing.

Behind every approved gene therapy for a rare disease, there is a community of patients, families, and advocates who refused to accept "nothing can be done" as an answer. Patient advocacy has been the single most important force in driving rare disease research forward.

Lipid nanoparticles are tiny spherical vesicles, typically 60 to 100 nanometers in diameter, composed of lipid (fat) molecules that self-assemble around a nucleic acid payload. They are not a single molecule but a carefully engineered mixture of four lipid components:

Victoria Gray, a mother from Mississippi, became the first person in the United States to receive CRISPR gene editing therapy for sickle cell disease in 2019 as part of the clinical trial. Her story put a human face on what had been an abstract scientific concept.

Casgevy, approved on December 8, 2023, holds a singular place in medical history as the first therapy based on CRISPR-Cas9 gene editing to receive FDA approval. It treats sickle cell disease in patients aged 12 and older with recurrent vaso-occlusive crises.

Casgevy is not the only gene therapy approved for sickle cell disease. Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio, received FDA approval on the same day as Casgevy in December 2023, also for patients aged 12 and older with SCD.

Recognizing that gene therapy is still a young field and that long-term safety and durability questions remain open, the FDA requires manufacturers of approved gene therapies to conduct long-term follow-up studies lasting 15 years after treatment.

Prime editing for F508del correction is arguably the most advanced genetic approach to CF, but it is not the only strategy under investigation. The field has diversified into several parallel paths, each with distinct advantages and challenges.

Phase 3 is the final and most rigorous stage of clinical testing before a company can apply for FDA approval. These are large-scale studies, enrolling between 1,000 and 3,000 patients — sometimes more — across multiple hospitals and countries.

The FDA approved Zolgensma on May 24, 2019, for the treatment of pediatric patients under 2 years of age with SMA. It was the most expensive drug in the world at the time of launch, with a list price of $2.125 million for a single dose.

Most patients do not pay for gene therapy out of pocket. The question is not whether a patient can afford $2 million — almost no one can — but whether their insurance will approve coverage and how the financial mechanics actually work.

No company better illustrates the fundamental tension in gene therapy economics than bluebird bio. The story of bluebird bio is a cautionary tale about what happens when transformative science collides with healthcare system economics.

The plausible mechanism pathway is likely to have the greatest impact on companies developing platform-based gene editing technologies -- those whose editing tools can be adapted to multiple diseases using the same core technology.

The commercial struggles of hemophilia gene therapy illuminate a broader crisis facing the gene therapy field. The fundamental tension is between one-time therapies and a healthcare payment system built around chronic treatment.

Before the 2026 pathway, the FDA already had several mechanisms to accelerate approval for therapies addressing serious conditions. Understanding these existing tools is essential context for why the new pathway was necessary.

The struggles of bluebird bio and BioMarin in Europe point to something deeper than individual company missteps. There is a structural mismatch between how gene therapies work and how healthcare systems pay for treatments.

Hemgenix (etranacogene dezaparvovec), developed by uniQure and commercialized by CSL Behring, became the first gene therapy approved in the United States for hemophilia B when it received FDA approval on November 22, 2022.

Nearly all hemophilia gene therapies in clinical development use adeno-associated virus (AAV) vectors to deliver a functional copy of the clotting factor gene to the liver, where clotting factors are naturally produced.

The list price of the CAR-T drug itself -- $373,000 to $475,000 -- is only part of the financial picture. The total cost of a CAR-T treatment episode, from initial evaluation through recovery, is substantially higher.

The following table lists every FDA-approved gene therapy and gene-modified cell therapy as of March 2026, organized by approval date. Following the table, we provide detailed narratives organized by therapy category.

Both therapies require myeloablative conditioning, which carries its own risks including infertility, infection, and organ damage. This remains one of the most significant burdens for patients considering treatment.

Now that you understand the fundamentals of gene therapy, let's explore one of its most remarkable applications: CAR-T cell therapy, where a patient's own immune cells are genetically reprogrammed to fight cancer.

The plausible mechanism pathway does not exist in isolation. It represents the latest step in a broader trend toward accelerated regulatory pathways for gene therapies -- a trend with a growing track record.

Several companies are now using LNPs to deliver CRISPR components directly into the body -- a paradigm called in vivo gene editing that eliminates the need to remove, modify, and reinfuse a patient's cells.

Once a company or research team believes their preclinical data is strong enough, they file an Investigational New Drug (IND) application with the FDA. This is the formal request to begin testing in humans.

CAR-T therapy is not chemotherapy, but it is far from side-effect-free. The engineered T cells trigger powerful immune reactions that can be life-threatening if not managed by experienced medical teams.

The sticker shock is real, and manufacturers know it. Every company that launches a gene therapy at a seven-figure price publishes a justification. The arguments generally fall into three categories.

Gene therapy for Parkinson's disease has evolved along several distinct strategies, each targeting a different aspect of the disease. Here are the major approaches currently in clinical development.

For patients living with Parkinson's disease, the emergence of gene therapy represents something more profound than a new treatment modality — it represents a change in what is possible to hope for.

Long before a therapy is tested in a single human being, it goes through years of preclinical research. This is the foundational work that happens in laboratories and, eventually, in animal models.

If DMD is caused by a missing protein, why not just deliver a working copy of the gene? That is exactly the idea behind gene therapy — but DMD presents a uniquely difficult engineering problem.

BioMarin's Roctavian (valoctocogene roxaparvovec) tells a more complicated story. It targets hemophilia A — the more common form — using an AAV5 vector carrying a B-domain-deleted FVIII gene.

As of April 2026, seven gene therapies carry list prices above $1 million in the United States. Several have crossed $3 million. One has broken $4 million. Here is the current landscape.

Vertex and CRISPR Therapeutics have been evaluating Casgevy in younger patients through the CLIMB PEDI-121 trial, a Phase 3 study enrolling children aged 2 to 11 with severe SCD or TDT.

The cost problem is bad. The access problem is worse. Even if money were no object, structural barriers would still prevent most eligible patients from receiving gene therapy in 2026.

The differences between approving a gene therapy and approving a conventional drug are not just procedural — they reflect fundamentally different scientific and economic realities.

To understand how gene therapy might help Parkinson's patients, you first need to understand what the disease does to the brain — and why current treatments eventually fall short.

The sticker shock is real, but the prices are not arbitrary. Several structural factors drive gene therapy costs into territory that no other class of medicine has ever reached.

Since August 2020, SMA patients have had three disease-modifying therapies available, each with a distinct mechanism of action, route of administration, and clinical profile.

Conducting clinical trials for rare disease gene therapies is unlike any other area of drug development. The challenges are profound, and they require creative solutions.

Before LNPs, the dominant delivery vehicles for gene therapy were viral vectors -- adeno-associated viruses (AAVs) and lentiviruses. LNPs offer several advantages:

Bringing a therapy as intensive as Casgevy to younger children introduces several challenges that clinicians, families, and regulators must navigate carefully.

Phase 1 is where a therapy first enters a human body. The primary goal is not to cure anyone. It is to answer one critical question: Is this therapy safe?

The gene therapy field is acutely aware that the current pricing and access model is unsustainable. Multiple approaches are being pursued simultaneously.

Duan, D., Goemans, N., Takeda, S., et al. "Duchenne muscular dystrophy." Nature Reviews Disease Primers, 7, 13 (2021). doi.org/10.1038/s41572-021-00248-3

The case for treating younger children is not simply about expanding a market. It is a medical imperative rooted in the biology of sickle cell disease.

Casgevy uses an ex vivo approach, meaning the patient's own cells are edited outside the body and then returned. The process works in several steps:

The durability of a gene therapy comes down to a surprisingly simple question: what happens to the new genetic material once it enters your cells?

While the regulatory and cost discussions in the United States and Europe are complex, they pale in comparison to the global access challenge.

Wild-type AAV is not ready for clinical use straight out of nature. Scientists have to re-engineer it. The process involves three major steps:

If your child has been diagnosed with DMD, or if you are considering gene therapy, here is practical guidance based on the current landscape.

The approval of Elevidys is a beginning, not an endpoint. The next decade will likely bring transformative advances in DMD gene therapy.

The most powerful argument for the plausible mechanism pathway is fundamentally ethical: patients with ultra-rare diseases cannot wait.

If you or someone you love is considering gene therapy, one of the first questions you will ask is: How long will this actually last?

Before diving into the complete list, it helps to understand the four major technology platforms used by approved gene therapies.

Understanding why Casgevy works requires a brief look at the biology of sickle cell disease and an elegant genetic workaround.

It is worth pausing to make a fundamental point that applies to all CRISPR-based therapies: the DNA edit itself is permanent.

Beyond the three approved products, several other gene therapy programs for hemophilia have been or remain in development.

If you are a patient or caregiver considering gene therapy, here is a realistic framework for thinking about durability:

Casgevy doesn't fix the mutated hemoglobin gene directly. Instead, it takes an elegant detour through fetal hemoglobin.

"Outside the body" — cells are removed from the patient, genetically modified in the laboratory, and then returned.

For patients considering CAR-T therapy, understanding the timeline and logistics helps set realistic expectations.

Even when insurance agrees to pay, patients face a gauntlet of practical barriers between diagnosis and treatment.

If Phase 1 establishes that a therapy is reasonably safe, Phase 2 asks the next logical question: Does it work?

AAV is not the only gene therapy vector. Several alternatives are gaining ground, each with distinct strengths:

Elevidys is the first but will not be the last. Several other approaches are in various stages of development.

Patients and clinicians naturally ask: how does gene therapy compare to DBS and other established treatments?

Let us look at the real-world evidence for some of the most important approved and late-stage gene therapies.

If you or a family member is considering gene therapy, here are the practical steps and resources available.

The journey of an AAV vector from injection to gene expression follows a precise series of biological steps:

Receiving Casgevy is not a simple outpatient procedure. The full treatment process spans several months:

For all its strengths, AAV has significant limitations that the field is actively working to overcome.

As of early 2026, the Parkinson's gene therapy landscape includes several active clinical programs:

The honest answer is: it depends on what you mean by "affordable," and for whom.

What happens if an AAV-based gene therapy fades? Can you just get another dose?

The journey of an LNP from injection to gene editing involves several steps:

If the biology of AAV is challenging, the manufacturing is equally daunting.

AAV dominates the gene therapy landscape for several converging reasons:

As of 2026, there are dozens of approved gene therapies worldwide:

The approval of Casgevy established several important precedents:

These terms are related but distinct: